On May 6, 2020, Bausch + Lomb and co-development partners STADA and Xbrane announced that they have entered into an exclusive licensing agreement with one another under which Bausch + Lomb will commercialize Xlucane, STADA and Xbrane’s proposed biosimilar of LUCENTIS (ranibizumab), if approved, in the United States and Canada. According to the press releases, STADA and Xbrane will be jointly responsible for finalizing development in the United States and Canada, Xbrane will provide commercial supplies of the product, and Bausch + Lomb will be responsible for the sales, marketing and all other commercialization efforts for the biosimilar candidate in the United States and Canada following regulatory approval.
As for the financials of the deal, the press releases indicate that “Bausch + Lomb will make a mid-single digit million USD up-front payment and will pay further milestone payments subject to approval and launch of the product in the United States. STADA and Xbrane will also be entitled to a share of gross profits from sales of the product by Bausch + Lomb, and will share equally in the proceeds they receive from Bausch + Lomb.”
The post STADA and Xbrane Ink Commercialization Deal with Bausch + Lomb for LUCENTIS Biosimilar Candidate appeared first on Big Molecule Watch.